San Mateo, CA
Summary
The company is dedicated to developing therapeutics that target dysregulated transcription, which is linked to cancer and autoimmune diseases. Their innovative approach involves analyzing transcriptional regulatory networks to identify critical nodes for drug development. They have several clinical candidates in their pipeline, including a CDK9 inhibitor for MYC-dependent tumors and a KAT inhibitor for Sjögren’s disease, and they collaborate with Genentech for further advancements in oncology.
Based on content on kronosbio.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
8.1 years — Since Nov 2016
Web Hosting
Platform
E-Mail Provider
Proofpoint
NAICS Code
325414
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Biotechnology focused on cancer and autoimmune disease therapeutics.
2. Biological Product (except Diagnostic) Manufacturing
Vendor
Source
Microsoft
TXT Record
Apple
TXT Record
DocuSign
TXT Record
TXT Record
Proofpoint
TXT Record
Smartsheet
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|